Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP5834 in Advanced Solid Tumors with KRAS Mutations/Amplifications
NCT07094204Phase 1Recruiting
- Sponsor
- Astellas Pharma
- Start
- Jul 2025
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of ASP5834 in solid tumor, non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC) and 1 more (6 arms), sponsored by Astellas Pharma. Primary endpoints: Dose Limiting Toxicities at 21 days, Adverse Events at 40 months and 9 more. Started Jul 2025; status: recruiting.
02
Drugs
ASP5834
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)pancreatic ductal adenocarcinoma (PDAC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07094204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07094204.